Bind appoints CEO
This article was originally published in Scrip
Executive Summary
Bind Therapeutics, a clinical-stage nanomedicine platform company developing targeted therapeutics called Accurins, has named Andrew Hirsch acting president and CEO. Mr Hirsch was formerly Bind's chief operating officer and chief financial officer. He replaces Scott Minick, who will remain a member of the company's board of directors. Bind intends to announce a permanent CEO following an "expeditious evaluation of internal and external candidates."